MR 4log and low levels of NK cells are associated with higher molecular relapse after imatinib discontinuation: Results of a prospective trial.
Sign Up to like & getrecommendations! Published in 2021 at "Leukemia research"
DOI: 10.1016/j.leukres.2021.106516
Abstract: BACKGROUND Treatment-free survival (TFS) in chronic myeloid leukemia (CML) is a new goal. This prospective study aims to evaluate imatinib discontinuation's feasibility and safety in patients with deep molecular response MR4 (BCR-ABL1 < 0.01 %… read more here.
Keywords: discontinuation results; median time; relapse; discontinuation ... See more keywords
Hope as a Lifeline: Imatinib Discontinuation in Patients With Oligometastatic Gastrointestinal Stromal Tumours
Sign Up to like & getrecommendations! Published in 2022 at "AntiCancer Research"
DOI: 10.21873/anticanres.15555
Abstract: Background/Aim: This study explored how highly selected oligometastatic gastrointestinal stromal tumour (GIST) patients subjectively experienced the discontinuation of imatinib (IM) treatment. Patients and Methods: Being an exploratory qualitative study, we applied a phenomenological and hermeneutical… read more here.
Keywords: lifeline imatinib; imatinib discontinuation; hope lifeline; oligometastatic gastrointestinal ... See more keywords